R Squared’s aTyr Pharma ATYR Stock Holding History

R Squared’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,255	Closed	-$8.81K	–	689
2025 Q4	$8.81K	Buy	+11,255	New	+$9.24K	﹤0.01%	510
2025 Q1	–	Sell	-870	Closed	-$3.15K	–	1567
2024 Q4	$3.15K	Buy	+870	New	+$2.63K	﹤0.01%	1402

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's ATYR Position: Q1 2026 in Review

R Squared sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 11,255 shares — an estimated $8.81K sold.

R Squared first reported a position in ATYR in Q4 2024 and held it in 2 quarters. The position peaked at $8.81K in Q4 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

R Squared reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
R Squared sold 11,255 aTyr Pharma shares in Q1 2026, an estimated $8.81K.
R Squared first reported a position in aTyr Pharma in Q4 2024 and held it in 2 quarters.
R Squared's aTyr Pharma position peaked at $8.81K in Q4 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.